Trial Profile
XENON AND COOLING THERAPY IN BABIES AT HIGH RISK OF BRAIN INJURY FOLLOWING POOR CONDITION AT BIRTH: A RANDOMISED OUTCOME STUDY (COOLXENON3 STUDY)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Xenon (Primary)
- Indications Brain hypoxia-ischaemia
- Focus Therapeutic Use
- Acronyms CoolXenon3
- 30 Aug 2022 Status changed from active, no longer recruiting to completed.
- 11 Nov 2019 Planned End Date changed from 31 Aug 2019 to 30 Sep 2021.
- 11 Nov 2019 Planned primary completion date changed from 31 Aug 2019 to 30 Sep 2021.